Cancer News and Research

Latest Cancer News and Research

Soy isoflavones can improve radiotherapy for lung cancer cells

A component in soybeans increases radiation's ability to kill lung cancer cells, according to a study published in the April issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

1 Apr 2011

LIFE Biosystems to present MASE data at AACR annual meeting

Adverse events, or side effects, have traditionally been viewed as an unavoidable consequence in the therapeutic treatment of cancer patients. Yet sufficient data exists to study the relationship between molecular mechanisms, and drug-induced phenotypes to learn about - and even predict - adverse events in patients.

1 Apr 2011

Aspen Dental reminds patients about oral cancer screening importance

Aspen Dental, one of the largest and fastest-growing networks of dental care providers in the U.S., is reminding patients about the importance of oral cancer screening and early detection in recognition of Oral Cancer Awareness Month.

1 Apr 2011

New research finds HIV virus's V3 loop as attractive vaccine target

A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Dana-Farber Cancer Institute scientists indicates.

1 Apr 2011

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

Blue Cross and Blue Shield of Minnesota reports $9 billion revenue for 2010

Blue Cross and Blue Shield of Minnesota and its family of companies (Blue Cross) today announced audited financial results for 2010. The nonprofit health company reported full-year 2010 revenues of $9 billion and an operating margin of 1.4%, which resulted in a net operating income of $127 million. This marks the second consecutive year of positive operating results, following three consecutive years of operating losses from 2006 to 2008.

1 Apr 2011

Rate of cancer deaths has declined in the U.S.

A report from the nation's leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2003 and 2007. The findings come from the latest Annual Report to the Nation on the Status of Cancer.

1 Apr 2011

TNM 7 system can predict lung cancer recurrence after surgery

The new TNM 7 lung cancer staging system seems to be a better predictor of local or regional recurrence of lung cancer following surgery, according to a study published in the April issue of the Journal of Thoracic Oncology.

1 Apr 2011

Closer to deciphering the 'language of the brain'

The moment we open our eyes, we perceive the world with apparent ease. But the question of how neurons in the retina encode what we "see" has been a tricky one. A key obstacle to understanding how our brain functions is that its components-neurons-respond in highly nonlinear ways to complex stimuli, making stimulus-response relationships extremely difficult to discern.

1 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

DNA damage can lead to regulation of inflammatory responses

Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Medicare moves to pay for Provenge

On Wednesday, Medicare officials signaled the federal insurance program will pay for this costly prostate cancer drug, a move that National Journal described as heading off "accusations that the [government] would be 'rationing' care."

1 Apr 2011

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

A study of newly installed, hands-free faucets at The Johns Hopkins Hospital, all equipped with the latest electronic-eye sensors to automatically detect hands and dispense preset amounts of water, shows they were more likely to be contaminated with one of the most common and hazardous bacteria in hospitals compared to old-style fixtures with separate handles for hot and cold water.

1 Apr 2011

Viewpoints: Controlling long-term-care spending; march madness and health reform; hospital physicians

Prepare to hear a lot about Medicaid, the government health-insurance program for the poor. ... The U.S. government can't put itself on a sustainable fiscal course without doing something to slow health spending. It can't slow health spending costs without treating Medicaid. And it can't treat Medicaid without confronting the fact that it has become the long-term-care insurer of last resort for an aging society.

1 Apr 2011

Syndax to present entinostat data against cancer at AACR meeting

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Positive outcome from Orexo's OX51 initial pharmacokinetic trial to treat acute intensive pain

Orexo AB announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief.

1 Apr 2011